The next frontier in vaccine design: blending immune correlates of protection into rational vaccine design.

"Conflict of interest statement The authors declare the following financial interests/personal relationships that may be considered as potential competing interests: GA is a cofounder and/or equity holder in SeromYx Systems Inc. and Leyden Labs. GA receives research funding from Pfizer, Sanofi, BioNtech, BMS, Gilead, Medicago, and GSK. GA’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. CB has no conflicts to disclose."

"We thank Mark and Lisa Schwartz, Terry and Susan Ragon, and the SAMANA Kay MGH Research Scholars award for their support. GA also receives funding from the Massachusetts Consortium on Pathogen Readiness (MassCPR), the Gates Global Health Vaccine Accelerator Platform, and the 10.13039/100000002NIH (3R37AI080289-11S1, R01AI146785, U19AI42790-01, U19AI135995-02, U19AI42790-01, P01AI1650721, U01CA260476 – 01, CIVIC75N93019C00052)."